Pharmaceuticals
News Category
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, marking a key step toward IND/C...
Sustained Release Polymers Market Set to Reach USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Drug Delivery Innovation
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by rising...
VERAXA Biotech Highlights BiTAC Pipeline Progress and Advances Partnering Strategy
VERAXA Biotech reported progress in its BiTAC platform and partnering strategy, with a pipeline of four BiTAC-based T-cell engager programs and plans ...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program, leveraging ATUM's Leap-In Transposase technology to advanc...
VERAXA Biotech AG: Strategic Partnerships in Antibody Therapeutics Highlight Sector Value
The article discusses how deal activity in antibody-drug conjugates and T-cell engagers creates value for companies like VERAXA Biotech AG, emphasizin...
Ace Therapeutics Launches Comprehensive Preclinical Analgesic Drug Development Services with Full-Spectrum Pain Research Platform
Ace Therapeutics announces end-to-end preclinical services for pain therapeutics, including diverse in vivo pain models and a full suite of research c...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve efficiency and counter sustained margin pr...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma reported fiscal 2026 financial results, highlighting over 88% enrollment in its Phase 3 APPROACH trial for HLP003, with topline data expe...
Voyageur Pharmaceuticals Enlists Fluor for Feasibility Studies on Iodine Production and Integrated Contrast Drug Facility
Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct feasibility studies for a domestic iodine extraction facility and an integrated cont...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has repaid the $60 million drawn from its revolving credit facility in June 2025 to finance the acquisition of Paladin, funded by ...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is assessing potential U.S. locations for a vertically integrated iodine and barium contrast media plant, aiming to secure do...
Earth Science Tech Inc. (ETST) Emerges as Diversified Holding Company in Telemedicine and Pharmacy
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals Submits Multi-Year Exploration Permit for Frances Creek Barite Project
Voyageur Pharmaceuticals has applied for a five-year advanced exploration permit at its Frances Creek barite project, aiming to produce 2,000 tonnes o...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for FDA Licensing and Project Development
Voyageur Pharmaceuticals closed a $5.0 million non-brokered private placement under the Listed Issuer Financing Exemption to fund FDA licensing for it...
Kairos Pharma Pipeline Expansion and Clinical Milestones Highlighted in Mid-Year Update
Kairos Pharma announced plans to acquire rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, and reported progress in its oncology pipeline...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities in BioMedWire Podcast
Quantum BioPharma discussed its lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd, emphasizing...
Quantum BioPharma Ltd. Advances Multiple Sclerosis Program with Lucid-MS Candidate
Quantum BioPharma's clinical-stage multiple sclerosis program targeting demyelination, coupled with a diversified portfolio spanning therapeutics and ...
Redwood AI Gains DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. achieves DTC eligibility for its shares, simplifying U.S. trading and enhancing liquidity, while also engaging IBN for a comprehensiv...
Carmed Pharmaceuticals Highlights CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is featured in CityBiz as it expands into th...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein and antibody synthesis in 3 hours, supporting AI-driven hi...
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox and Other Viral Diseases
NanoViricides reported progress on NV-387, its broad-spectrum antiviral candidate, including regulatory approval for Phase II trials in the DRC for MP...
NanoViricides Prices $2 Million Registered Direct Offering to Fund Antiviral Drug Development
NanoViricides announced a $2 million registered direct offering with a single institutional investor to advance its broad-spectrum antiviral drug NV-3...
Lantern Pharma Closes $4.4 Million Direct Offering, Strengthening Financial Position for AI-Driven Cancer Drug Development
Lantern Pharma raised $4.4 million in a registered direct offering, with potential additional proceeds from warrants, to advance its precision oncolog...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May
Tonix Pharmaceuticals management will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Virtual Healthcare Conference in Ma...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma announces the expansion of its predictBBB platform into a Large Quantitative Model, providing researchers with a real-time molecular in...
LIXTE Biotechnology’s LB-100 Positions as Novel Enhancer of Cancer Therapies
LIXTE Biotechnology is advancing LB-100, a first-in-class PP2A inhibitor designed to boost the effectiveness of existing cancer treatments, with ongoi...
Soligenix’s Platform Strategy Highlighted for Efficient Drug Development Across Multiple Indications
Soligenix leverages its synthetic hypericin platform to target both cutaneous T-cell lymphoma and psoriasis, demonstrating how platform-based drug dev...
PolyPeptide Shareholders Approve All Board Proposals at Annual General Meeting
PolyPeptide Group AG's shareholders approved all board proposals, including re-election of directors and compensation packages, affirming confidence i...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlighting Transformational Year with Clinical Progress and Strategic Acquisition
LIXTE Biotechnology Holdings filed its 2025 Form 10-K, detailing leadership changes, clinical advancement of LB-100, acquisition of Liora Technologies...
LIXTE Biotechnology's LB-100: The World's Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology holds the only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapies and disrupts repair syst...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates former Eli Lilly executive Stephen Fry to its Board, aiming to strengthen its performance culture and organizational transformation wi...
Voyageur Advances Barium and Iodine Contrast Media Projects with Bankable Feasibility Studies and FDA Submission
Voyageur Pharmaceuticals is progressing its vertically integrated barium and iodine contrast media projects, targeting FDA approval by mid-2027 and co...
Soligenix Secures Key European Milestone for Dusquetide Development in Behcet's Disease
Soligenix receives positive EMA opinion for orphan drug designation of dusquetide in Behcet's disease, unlocking development incentives and validating...
Netherton NOW Campaign Surpasses 2 Million Video Views, Amplifying Rare Disease Awareness
Quoin Pharmaceuticals' NETHERTON NOW campaign has achieved 2 million video views and 24 million impressions, highlighting the urgent need for treatmen...
Oncotelic Therapeutics Featured in Editorial Highlighting Late-Stage Biotech M&A Trends
Oncotelic Therapeutics was featured in a BioMedWire editorial discussing how pharmaceutical companies are prioritizing late-stage, de-risked assets in...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that a Phase 2a trial of SPL026 met its primary endpoint, showing significant reductions in depressive symptoms, with results p...